H. Lundbeck A/S announced on 16 September 2026 that Japan’s Ministry of Health, Labour and Welfare had granted marketing authorisation for eptinezumab for the prevention of migraine attacks in adults, according to the company press release opened via PR Newswire UK, datelined Valby, Denmark. Contacts and “About Lundbeck” boilerplate in the same release are corporate colour and are not used for hed facts. No MHLW.go.jp approval bulletin or Japanese package-insert PDF was opened this pack; authorisation fact and indication wording are taken from Lundbeck’s release.
Named product and mechanism as Lundbeck states them: eptinezumab is a humanized monoclonal antibody that binds calcitonin gene-related peptide (CGRP) and was developed for intravenous administration as preventive migraine treatment. Lundbeck characterises it as the only IV CGRP-targeted preventive treatment approved for adults and states it is launched in more than 30 countries — company comparative claims. U.S. FDA approval in February 2020 and European Commission authorisation in January 2022 are stated as prior history in the same release.
Evidence package as Lundbeck describes it for Japan: the Japanese marketing authorisation is supported by the global clinical development programme, including Phase III PROMISE-1, PROMISE-2 and DELIVER, together with the Phase III SUNRISE trial in a predominantly Asian chronic-migraine population, with further support from the Phase III SUNSET long-term extension in Japanese patients for long-term safety. Efficacy numbers from PROMISE-1/2 (monthly migraine-day reductions) are summarised in the release’s “About Vyepti” section as meeting primary endpoints over weeks 1–12 — secondary company summary, not trial PDFs opened here. Common adverse reactions listed for placebo-controlled preventive trials are hypersensitivity and infusion-related reactions — company label-style summary.
Commercial path: Lundbeck says the approval paves the way for the company’s first launch in Japan as marketing authorisation holder, enabling it to operate independently on the Japanese market after 25 years of commitment in the country. Launch timing, price and reimbursement are not set in the opened release; authorisation is not the same as reimbursed availability. The release’s safety paragraph states eptinezumab has been evaluated in more than 5,000 adult patients who received at least one dose — a company aggregate, not a Japan-only safety database opened here.
Disease context numbers in the release (8.4%–11.0% prevalence estimates; fourth leading cause of years lived with disability; ~US$3 billion annual productivity cost) are cited to older papers and are secondary epidemiology if used outside the company handout; they are kept out of hed and dek here.
What to watch without mood: Lundbeck’s Japan launch date as MAH; NHI pricing/listing steps; uptake versus other CGRP pathway preventives already available in Japan; and any MHLW or PMDA post-marketing commitments not detailed in the company release.
Floor: Lundbeck 16 Sep — MHLW marketing authorisation for eptinezumab (Vyepti) for prevention of migraine attacks in adults (IV CGRP mAb); supported by PROMISE/DELIVER + SUNRISE + SUNSET (co.); first Lundbeck Japan launch as MAH planned. Company PR only — no MHLW primary bulletin opened.